Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: -0.25 (-1.75%)
Spread: 1.00 (7.407%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IQE Latest To Clarify Director Share Dealings With Equities First

Thu, 13th Nov 2014 14:24

LONDON (Alliance News) - IQE PLC Thursday became the latest AIM-listed company to clarify directors' share dealings and agreements with Equities First Holdings, saying its chief executive entered a share sale and repurchase agreement with the US stock loan company in order to finance the acquisition of shares and to meet tax and national insurance obligations on the exercise of options in October.

IQE's clarification follows similar moves earlier this week by Cloudbuy PLC, ANGLE PLC, and Quindell PLC to give more detail to the market regarding their own directors' agreements with Equities First. Although Quindell said three directors, Chairman Robert Terry, Finance Director Laurence Moorse and Non-Executive Director Steve Scott, agreed funding deals to pay for the acquisitions of the company's shares, its stock price has been under pressure, with about 35% of its value wiped in the last five days.

Meanwhile, Cloudbuy's chairman, Ronald Duncan entered the deal to secure funding in connection with moving house, while ANGLE also cited a house move as the reason for Chief Executive Andrew Newland's decision to arrange his financing deal with Equities First.

IGas Energy PLC, another company to have become associated with the issue, is yet to clarify a deal done by its chief executive earlier this year. On January 16, IGas said that Chief Executive Andrew Austin bought 300,000 shares in the company, funded with a loan from Equities First that was secured by some of his existing holdings. IGas was not immediately available for comment.

In a statement, IQE said that Drew Nelson entered the sale and repurchase agreement for a total of 18 million shares, raising GBP1.865 million before commissions of GBP55,944. On October 14, IQE had said directors "entered into loan agreements and have transferred a total of 18 million existing shares as security" and that they are "required to redeem the transferred shares at maturity when the loan is repaid at the end of the three year term".

Under the deal, Nelson must repurchase all the shares at the end of a three-year term, ending on October 10, 2017. According to IQE, the price at which he is required to repurchase the shares is 11.4 pence per share.

"The agreement provides that he has transferred all title and waives his voting rights in these shares," IQE said.

However, the company reiterated that Equities First is "prohibited from short selling or voting the shares" during the term of the agreement.

In addition, IQE said that Equities First will pay Nelson income from dividends paid by IQE during the entire period, as if Nelson had continued owning all the shares himself.

As part of the arrangement, IQE said, Finance Director Phillip Rasmussen and Operations Director Howard Williamns agreed to enter into separate loan agreements with Nelson by pledging 2.72 million shares each to him as security for money he has lent to them. According to IQE, Rasmussen has provided loans of GBP274,000 to each of them.

IQE said that about 52% of the money raised by the executive directors has already been used to fund the purchase of the shares and to meet income tax and National Insurance obligations following the exercise of share options announced by the company on October 10.

IQE said the directors opted to raise the money for income tax and National Insurance through the alternative arrangements instead of selling a portion of the shares acquired on exercising the options.

"In the case of the IQE directors, they have elected to raise the tax and NI monies through these arrangements in order to retain all of the exercised share options, thereby increasing their respective holdings in the company, in addition to purchasing additional shares. The remainder of the monies raised is intended to be used to fund further tax liabilities and NI due on the exercise of share options which are due to vest in early 2015, as well as fund further share purchases and cover any potential margin calls under the share sale and repurchase agreement," IQE said.

IQE noted that the share option exercises were part of the company's long-term incentive plan. It said the directors were under "no
time obligation to exercise such share options, but chose to do so at this time in order to maximise their respective shareholdings in the company".

Equities First hasn't responded to request for comment from Alliance News.

The following is a table provided by IQE on Thursday regarding the directors' share dealings and holdings:

|Name          |No. of       |Option   |No. of      |No. of        |Ordinary   |
| |Ordinary |Exercise |Ordinary |Ordinary |Shares as a|
| |Shares prior | |Shares |Shares after |% of ISC |
| |to | |purchased |exercise and | |
| |option | | |purchase | |
| |exercise | | | | |
+--------------+-------------+---------+------------+--------------+-----------+
|Dr. Drew |28,658,465 |4,800,753|1,800,000 |35,259,218 * |5.34% |
|Nelson, CEO | | | | | |
+--------------+-------------+---------+------------+--------------+-----------+
|Phillip |852,822 |1,870,535|750,000 |3,473,357 |0.53% |
|Rasmussen, CFO| | | | | |
+--------------+-------------+---------+------------+--------------+-----------+
|Dr. Howard |1,672,430 |1,870,535|750,000 |4,292,965 |0.65% |
|Williams, COO | | | | | |
| | | | | | |
|Totals** |31,183,717 |8,541,823|3,300,000 |43,025,540 |6.54% |
+--------------+-------------+---------+------------+--------------+-----------+
"*These include the 18 million shares that Dr Drew Nelson sold but retains the obligation to repurchase
"** In aggregate, using the share and repurchase agreement and associated inter-director loans, the directors
have increased their interests in the companys shares by a total of 11,841,823 shares or 38%," the company said.


IQE shares were down 1.5% at 16.25 pence on Thursday.

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
5 Jun 2024 16:32

EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 Jun 2024 10:08

Angle unveils plans to raise more than £10m

(Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.

Read more
16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
16 May 2024 11:46

Angle reports promising results from Parsortix study

(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be used to predict progression-free survival in patients with ovarian cancer.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
3 May 2024 08:48

LONDON MARKET OPEN: Confident start before US jobs data

(Alliance News) - Stock prices in London opened higher on Friday, on the rising conviction that the afternoon's US jobs report will be softer, cooling some hawkish Federal Reserve interest rate expectations.

Read more
3 May 2024 07:58

Angle strikes supplier deal with AstraZeneca

(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.